NPAT fell 71.9% as portfolio gains cooled; coverage dropped to 39.4%

Annolyse's historical baseline puts that NZ$12.5m at the lower edge of the four-period range (mean NZ$25.3m), so the prior period was the unusually strong comparator rather than this period being a structural break.

Investment income itself moved the other way: dividends plus interest rose 16.2% to NZ$4.8m, an unprecedented high against a four-period mean of NZ$3.8m. Net assets attributable to shareholders also reached a record NZ$240.6m (+11.5%), versus a historical mean of NZ$192.9m, and cash on the balance sheet jumped to NZ$22.0m from NZ$5.8m. ROE compressed to 3.3% (prior 13.0%), at the lower edge of the supplied historical range.

Distributions paid during the year totalled NZ$12.3m against NZ$4.8m of investment income, so distribution coverage by income fell to 39.4% — the bottom of the supplied historical range. For a listed investment company, that means realised and unrealised portfolio gains, not dividend and interest receipts, are funding the payout. Sustainability is therefore tied to portfolio performance rather than a steady income stream.

Portfolio return weakness, not income, drove the NPAT decline. The drop from NZ$33.1m of investment total return last year to NZ$12.5m this year explains essentially all of the earnings collapse. The Australian-equity benchmark used by the company sat at 70.0%, which Annolyse's baseline classifies as within its normal range, so the question is how much of the gap is fund-specific stock selection versus a general moderation in Australian small/mid-cap gains after a very strong prior year.

The income line is the durable bright spot. Dividends and interest of NZ$4.8m printed above every period in the four-year baseline. If sustained, that lifts the floor under future distribution coverage even if capital gains normalise from the FY24 high.

Shape context is informative, however: HY25 NPAT was NZ$8.9m, while the full-year NPAT was NZ$7.9m, implying a roughly NZ$1.0m loss in the second half. The H1 share of full-year NPAT therefore exceeded 100%, indicating the portfolio gave back gains between January and June rather than building on the interim result.

That second-half softness, against a still within-range benchmark return, is the most important forward-looking signal in this release. It matters because distribution coverage already sits at 39.4%; another period of muted portfolio return would put further pressure on the capacity to fund distributions without drawing on capital.

That is the part of the result a shareholder can most reasonably extrapolate.

The earnings line is lower quality. NPAT for a listed investment company is dominated by fair-value movements that are inherently timing-driven, and this year's NZ$12.5m total return sits at the bottom of the supplied historical band. The effective tax rate also rose to 6.5%, an unprecedented high versus a four-period mean of 1.5%, which widened the gap between PBT (-70.7%) and NPAT (-71.9%) by 1.2 percentage points — small in dollar terms but a fresh drag worth tracking. Operating cash flow swung to a NZ$0.5m outflow from a NZ$11.3m inflow, but for an LIC this primarily reflects the timing of portfolio purchases, sales and dividend receipts rather than a working-capital problem; the closing cash balance of NZ$22.0m is materially higher than a year earlier.

This briefing cannot assess the manager's stock-level positioning, fee structure, or fund-versus-benchmark performance attribution because expense ratio, portfolio total return percentage and holdings detail were not supplied.